Latest News
Plasma ACE2 Found to Be Associated With Risk for Major Cardiovascular Events
Reversing Factor Xa Inhibitor–Related Bleeding With 4-Factor-Prothrombin Complex Concentrate
Flavan-3-ol Intake May Lower Systolic Blood Pressure
Lipid-Lowering Medications Found to Lower Risk for Cancer Death
Endocan Level May Predict No-Reflow Phenomenon During Primary PCI for STEMI
Risk for CVD in Women vs Men With Diabetes
Treatment With Antihypertensive Agents Associated With Decreased Risk for Depression
Weekend Admission for Stroke Tied to Higher Mortality
Aortic Dissection, a Rare Complication of Pregnancy
Polypharmacy Common in Older Patients Hospitalized for Heart Failure
Outcomes With Early vs Nonearly Coronary Angiography for Out-of-Hospital Cardiac Arrest Without STE
Higher Levothyroxine Doses Linked to Afib in Older Patients
Cardiac, Metabolic Morbidity Highly Prevalent in Patients With Alopecia Areata
Risk for Severe COVID-19 Low With Congenital Heart Disease
Latest Features
Expert Q&A: Reassessing Risk-Based LDL-C Targets
Lipid-lowering therapies are key to the prevention of cardiovascular (CV) events and CV-related mortality.
Thrombotic Thrombocytopenic Purpura: Expert Recommendations, Good Practice Statements for Critical Care
TTP is a rare disease that clinicians may not often treat; however, it is important to be aware of new developments for the treatment of this patient population.
The Lipid Paradox and CVD Risk in Rheumatoid Arthritis
Mechanistic and outcomes studies are warranted to elucidate the lipid paradox and CVD risk in rheumatoid arthritis (RA).
-
Loading...
-
Loading...
